The Novavax Covid vaccine, which has just received the green light from the European Medicines Agency Ema, “is a vaccine called a protein subunit, a technology already widely used in other vaccines: we take a purified protein of the virus, which is inoculated and stimulates the response immune system in a similar way to some older vaccines such as hepatitis B vaccines. ” However “we are not talking about a vaccine with fewer side effects or risk-free a priori. Like all vaccines it can have its adverse reactions, its abnormal responses“. Marco Falcone, associate professor of infectious diseases at the University of Pisa and secretary of Simit (Italian Society of Infectious and Tropical Diseases) specifies, who spoke to ‘Gli Inascoltabili’ on New Sound Level radio.
“The difference is that” the Novavax vaccine “uses a platform that is not as innovative as the mRna one – specifies the specialist – but one that has already been tested in the past that could make people who have reservations about the newest technologies calmer”. That said, “there are no elements to have doubts and reservations about mRna vaccines – assures Falcone -. Many suspicious people, in order not to do that with mRna, have preferred to make the Johnson & Johnson and AstraZeneca viral vector vaccines, which were then those with greater side effects and less efficacy. By J&J it is now known that the single-dose is completely ineffective in preventing the disease. Conversely, with one and a half billion mRna vaccines in the world, there are no huge problems “.